VPTDF Stock UPDATES Ventripoint Diagnostics Ltd. (VPTDF) 0.0500

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ventripoint Diagnostics Ltd. (VPTDF) 0.0500 $VPTDF

German Heart Group Verifies Accuracy of Ventripoint's VMS(TM) Heart Analysis Technology for Cardiac MRI and 3D Echocardiography Imaging
Marketwire - Mon Jul 07, 10:22AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) announces that a group led by Dr. Kai Laser at the Center for Congenital Heart Defects, Bad Oeynhausen, Germany, has published the results of a clinical study that demonstrates the robust application of the VMS heart analysis technology beyond 2D ultrasound imaging in a wide range of cardiac conditions.

Ventripoint to Exhibit at the 25th Annual Scientific Sessions of the American Society of Echocardiography
Marketwire - Fri Jun 20, 8:08AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) announces that it will be exhibiting at the 25th Annual Scientific Sessions hosted by the American Society of Echocardiography (ASE) in Portland, Oregon, held June 20th through June 24th.

IIROC Trade Resumption - VentriPoint Diagnostics Ltd.
Newsfile Corp - Mon Mar 10, 8:35AM CDT
Trading resumes in:

FDA Clears Ventripoint VMS(TM) Heart Analysis System for Use in Patients with Pulmonary Arterial Hypertension
Marketwire - Mon Mar 10, 7:24AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) announces that the US Food and Drug Administration (FDA) has cleared the VMS(TM) heart analysis system to be an adjunct to all existing 2D ultrasound imaging devices to allow computation of the 3D volume and ejection fraction of the right heart in patients with Pulmonary Arterial Hypertension (PAH).

IIROC Trade Halt - VentriPoint Diagnostics Ltd.
Newsfile Corp - Fri Mar 07, 2:55PM CST
The following issues have been halted by IIROC:

Oculus Innovative Sciences, Inc. to Raise $1.35 Million in Registered Direct Offering
GlobeNewswire - Fri Feb 21, 9:00PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced today that it has entered into definitive agreements with two life sciences-focused institutional investors for the sale of 450,620 units, consisting of shares of common stock, and Series A and Series B warrants, at a per unit price of $3.00 per share. The total amount sold consisted of a combination of: (1) 450,620 shares of its common stock; (2) Series A warrants to purchase up to 450,620 shares of common stock at an exercise price of $3.00 per share and a term of five years; and (3) Series B warrants to purchase up to 1,400,000 shares of common stock at an exercise price of $3.63 per share. The Series B warrants are not exercisable for six months following the closing of the IPO and have a term of 18 months. The Series B warrants have not vested and will not vest until the completion of the initial public offering (IPO) by the company's subsidiary, Ruthigen, Inc. The Series B warrants terminate on March 31, 2014, if the Ruthigen IPO has not occurred by that date.

Ventripoint Announces 510(k) Submission for VMS Heart Analysis System and Issuance of Shares for Debt
Marketwire - Thu Jan 23, 6:01AM CST
Ventripoint Diagnostics Ltd. (TSX VENTURE: VPT) is pleased to announce that it has submitted to the US Federal Drug Administration ("the Agency" a new 510(k) for clearance for the VMS(TM) heart analysis system for use in Pulmonary Arterial Hypertension (PAH).

Yieldex Wraps Up 2013 With 1.5 Trillion Impressions
Marketwire - Thu Dec 19, 8:30AM CST
Yieldex, the leading provider of inventory and revenue management solutions for digital publishers, today announced that 1.5 trillion ad impressions have been analyzed via the YieldEdge platform this year, demonstrating that companies are increasing their investment and reliance on big data analytics to grow their businesses.

Ventripoint Announces Regulatory Update for VMS(tm) Heart Analysis System
ACCESSWIRE - Fri Dec 13, 4:29PM CST
Seattle, Washington, December 13, 2013 - Ventripoint Diagnostics Ltd. (TSXV:VPT) (the Company or Ventripoint) is pleased to announce that the it has responded within the specified 30-day period to the non-substantially equivalent (NSE) letter received from the U.S. FDA on November 14, 2013, and has had numerous discussions with the FDA to identify the best and quickest pathway to obtain clearance for the VMS(TM) heart analysis system for use in Pulmonary Arterial Hypertension (PAH).

Ventripoint Announces Closing of Private Placement
Marketwire - Mon Jul 29, 5:49PM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company" (TSX VENTURE: VPT) (OTCQX: VPTDF) announces that it has completed the second closing of the second of its two previously announced non-brokered private placements.

University of Chicago Publishes First Results Using Ventripoint Heart Analysis System in Pulmonary Arterial Hypertension in Prestigous Medical Journal
Marketwire - Thu Jul 25, 6:01AM CDT
Ventripoint Diagnostics (TSX VENTURE: VPT)(OTCQX: VPTDF) is pleased to announce that the cardiology group from the University of Chicago, led by Dr. Roberto Lang, has published a paper entitled "Three-Dimensional Modeling of the Right Ventricle from Two-Dimensional Transthoracic Echocardiographic Images: Utility of Knowledge-Based Reconstruction(i) in Pulmonary Arterial Hypertension" in the Journal of the American Society of Echocardiography, Volume 26, Issue 8, Pages 860-867, August 2013.

VentriPoint Announces Closing of Private Placement and Corporate Update
Marketwire - Mon Jun 24, 6:01AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company" (TSX VENTURE: VPT)(OTCQX: VPTDF) announces that it has completed a first closing of the second of its two previously announced non-brokered private placements and is providing a corporate update.

Ventripoint Announces New Vice-President of Sales and Marketing
Marketwire - Thu May 30, 11:54AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company" (TSX VENTURE: VPT)(OTCQX: VPTDF) announces that it has hired Mr. Jerry Gatewood as its Vice-President of Sales and Marketing.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 250

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 88

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 273

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 241

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 322

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 393

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 47

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
IS: Thai Approval Opens New Sarcoma Treatment Path"> Continue Reading